Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’
10.1136/annrheumdis-2020-218836
September 21, 2020
COVID-19
Correspondence to ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’
10.1136/annrheumdis-2020-218797
September 21, 2020
Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold?
10.1136/annrheumdis-2020-218738
September 15, 2020
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M . The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patientset al
10.1136/annrheumdis-2020-218813
September 15, 2020
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti ’ by Chen et al
10.1136/annrheumdis-2020-218909
September 9, 2020
Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al
10.1136/annrheumdis-2020-218876
September 9, 2020
Response to: ‘Implications of SARS-CoV-2 infection for patients with rheumatic disease’ by Lin et al
10.1136/annrheumdis-2020-218404
September 7, 2020
Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic
10.1136/annrheumdis-2020-218756
September 7, 2020
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al
10.1136/annrheumdis-2020-218910
September 7, 2020
Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al
10.1136/annrheumdis-2020-218791
September 7, 2020